基于GPR119靶点的抗糖尿病药物研究进展  

Progress in antidiabetics based on GPR119

作　　者：赵立霞[1] 于洋[1] 王志强[1] 孙铁民[1] 

机构地区：[1]沈阳药科大学创新药物研究与设计教育部重点实验室,辽宁沈阳110016

出　　处：《中国药物化学杂志》2012年第5期393-402,共10页Chinese Journal of Medicinal Chemistry

摘　　要：糖尿病是一种常见的慢性代谢性疾病,主要表现为高血糖及一些微血管并发症,严重影响人类的健康。随着对糖尿病发病机制的深入研究,出现了许多具有新作用靶点和新作用机制的药物。其中G蛋白偶联受体119激动剂受到人们的关注。本文对基于GPR119靶点的抗糖尿病药物的研究进行综述。Diabetes mellitus, an epidemic metabolic disorder characterized by high blood glucose level associ- ated with various microvascular complications, affects the human health seriously. With the advance of the pathogenesis of diabetic research, many drugs with new targets and new mechanism are explored. Among them,G protein-coupled receptor 119 （GPRll9）activator has increasingly been come under recognition. Here, several types of GPR119 agonists such as six-membered heterocyclic ring-based agonists, five-mem- bered heterocyclic ring-based agonists, bicyclic core-based agonists and linear core-based agonists were reviewed.

关 键 词：G蛋白偶联受体119 抗糖尿病药物 激动剂 

分 类 号：R977.15[医药卫生—药品]